Close the Gap

CLOSE THE GAP BETWEEN INNOVATION AND IMPACT

Diagnostic-driven therapies need more than ‘launch and in market as usual’. What’s more, testing gaps, pathway blind spots and delayed engagement still stand between scientific innovation and real patient impact. Explore why commercialization has to work differently—and why now is the moment for our industry to come together to close the gaps.

Download report

THE REPORT: IN BRIEF

Why the gap still exists

Science has advanced. Testing has improved. But eligible patients are still being lost between diagnosis, treatment decisions and therapy adoption. Explore the evidence behind the gap between innovation and impact.

The decision point now matters most

The largest gap now sits at the point of treatment decision. Explore why better testing alone is not enough, and why teams need clearer intelligence and engagement when decisions are still forming.

The model has to change

Diagnostic-driven therapies cannot rely on launch models built for broad markets. See what changes when diagnostic insight, real-world data, scientific expertise and targeted engagement work together.

TURN EVIDENCE INTO ACTION

Diagnostic-driven therapies are changing what’s possible for patients. But the commercial model has not kept pace.

Testing has improved. Data has multiplied. Earlier diagnostic steps have advanced. Yet too many eligible patients are still lost between diagnosis, interpretation, treatment decision and therapy adoption.

Closing the gap means moving beyond more data, more channels and more disconnected activity. It means connecting intelligence and engagement around the moments that decide whether a patient moves forward.

Explore what needs to change—and where biopharma teams can act now.

BUILT ON MORE THAN A POINT OF VIEW

For more than two decades, Diaceutics has worked where diagnostics, data and commercialization meet—building towards our vision of Precision for All.

Our perspective is shaped by Practice Gaps research, customer insight, real-world case studies and direct relationships across the Diaceutics Lab Network. Together, these show where patients are lost, where decisions stall and where action can change what happens next.

Explore the evidence driving change. Then stay connected to the insight, ideas and action helping biopharma teams close the gaps between diagnostic progress and real patient impact.